2023 年 2 巻 3 号 p. 50-59
Background: Absolute lymphocyte count (ALC) and neutrophil lymphocyte rate (NLR) as immune system and inflammatory markers have been suggested as prognostic factors in eribulin treatment. However, the respective cut-off values have not been determined. Hence, we investigated the relationship between overall survival (OS) and baseline ALC (bALC) and baseline NLR (bNLR) in eribulin-treated patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) by using 2 types of cut-off values for each.
Methods: Univariate and multivariate analyses were performed to investigate the association of bALC and bNLR with OS among 114 female patients with HER2-negative BC treated with eribulin.
Results: The OS of patients with HER2-negative BC was compared based on bALC (cut-off value: 1,200/μL and 1,500/μL) and bNLR (cut-off values: 2 and 3). A significant difference was observed in median OS between patients with bALC of ≥ 1,200/μL and those with bALC of < 1,200/μL (hazard ratio [HR]: 0.596 [0.395, 0.889], p = 0.014). For bNLR (cut-off value: 2), the median OS was significantly higher in patients with a bNLR of < 2 than in those with a bNLR of ≥ 2 (HR: 0.629 [0.406, 0.974], p = 0.038).
Conclusions: Patients with HER2-negative BC with a bALC of ≥ 1,200/μL showed a longer OS than patients with a bALC of < 1,200/μL, thus suggesting that survival prediction using bALC was effective for eribulin-treated patients with recurrent HER2-negative BC. It should be noted that the optimal cut-off value for ALC may change depending on the target patient group.
